ERCC1

excision repair cross-complementation group 1 - an enzyme active in DNA repair and therefore a sign of resistance to treatments that work by disrupting tumor DNA. Cancers that may benefit from testing for this biomarker: lung (non-small cell and small cell), gastric, ovarian, colorectal, bladder

resistance to cisplatin (Platinol®), carboplatin (Paraplatin®), oxaliplatin (Eloxatin®)